Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry
S. Graff (Liege, Belgium), G. Brusselle (Ghent, Belgium), S. Hanon (Brussels, Belgium), C. Sohy (Louvain, Belgium), L. Dupont (Leuven, Belgium), R. Peche (Charleroi, Belgium), A. Michils (Brussels, Belgium), C. Pilette (Brussels, Belgium), G. Joos (Ghent, Belgium), R. Louis (Liege, Belgium), F. Schleich (Liege, Belgium)
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Graff (Liege, Belgium), G. Brusselle (Ghent, Belgium), S. Hanon (Brussels, Belgium), C. Sohy (Louvain, Belgium), L. Dupont (Leuven, Belgium), R. Peche (Charleroi, Belgium), A. Michils (Brussels, Belgium), C. Pilette (Brussels, Belgium), G. Joos (Ghent, Belgium), R. Louis (Liege, Belgium), F. Schleich (Liege, Belgium). Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry. 3109
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: